News

Scientists have developed a versatile imaging system that will help diagnose pathologies in the eye fundus.

The suspension is unrelated to product quality and will lift in February of 2024.

During a multidisciplinary meeting with FDA, based on preliminary results from an ongoing Phase 1/2 study, the company received alignment on key points of the Phase 3 study design.

Government focus on preventing blindness as well as rising elderly population are key drivers behind this growth.

A genome topology map of human retina development lays the foundation for understanding diverse clinical phenotypes in simple and complex eye diseases.

According to the company, if approved, OCS-01 has the potential to become the first topical eye drop and non-invasive treatment option for DME.

Glaukos Corp's iDose TR has received FDA approval for the reduction of IOP in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG) following a new drug application (NDA) submission.

According to the company, the Regenerative Medicine Advanced Therapy designation will help expedite the development of new regenerative medicines.

Randomization has been completed and, according to the company, topline data is expected during the third quarter of 2024.

According to the company, the acquisition will extend its leadership in ophthalmic medical devices market and expands its position in the vitreo-retinal surgery segment.

Gather, participate, learn, socialize

The 24th annual Retina Fellows Forum will take place on January 25 and 26, 2024 in Chicago at the Westin Chicago River North hotel.

Boneva is an experienced surgeon skilled in trauma, surgical critical care, emergency surgery, and acute care surgery.

The research marks the first attempt at integrating a photoactivatable anti-angiogenic agent with a photosensitizer into a single nanoformulation for AMD treatment.

The kidney and eye are structurally and functionally similar, and the diseases of the organs may present similarly and via common pathways.

Umedaptanib pegol has potential to improve outcomes if used as a first-line medication prior to patients receiving treatments targeting VEGF.

According to the company, OCU410 is a modifier gene therapy product candidate being developed for dry AMD.

Sblendorio brings decades of experience in the ophthalmic industry to his position on the Nanoscope board as the company continues to move forward in their commitment to retinal diseases.

The partnership will further the effort to bring VGX-0111, a gene therapy treatment for AMD to patients and providers.

The study saw encouraging results and helped to identify suitable dosing levels for future clinical trials.

LambdaVision seeks to cure genetic blindness with a protein-based artificial retina. Harnessing microgravity in low-Earth orbit, the company collaborates with NASA and the ISS to perfect its manufacturing process.

The company’s lead ophthalmology candidate, EXN407, has the potential to be the first topical treatment for DR/DME.

Earlier this year, Harrow acquired the US commercial rights to Triesence. Aside from the transfer of the Triesence NDA ahead of the date previously agreed to, all other acquisition terms remain unchanged.

The drug is being evaluated on its safety, tolerability and pharmacokinetics of intravitreal single-rising doses and multiple doses as a potential treatment for GA.

The company has come into agreement with IQVIA Services Japan G.K. as well as AUROLAB.

Both oxidative stress and HIF-1 have been previously implicated in the development of AMD, but this research more clearly shows how cells are affected.

The predictive factors were the previous number of anti-vascular endothelial growth factor and the photometry laser flare-cell (LFCP) value.

Austrian investigators advise establishing an interdisciplinary setting, ie, rheumatologic–ophthalmologic, to improve management of patients with rheumatic diseases.